High content screening (HCS) is a mature screening technology that has penetrated all stages of the drug discovery pipeline. It is a powerful analytical tool that yields biologically relevant and statistically robust data, unique in its ability to extract multiparametric, information-rich data from cellular models.
Selvita has at its disposal a new high-content imaging system based on Perkin Elmer Operetta CLS, a high throughput widefield and confocal imager with 2D, 3D and live imaging capabilities, integrated with artificial intelligence analytical solutions. Images generated by the HCS system can be analyzed by either human-defined or AI-based protocols, depending on specific needs.
HCS can be applied in secondary screening (e.g., compounds profiling and characterization in phenotypic in vitro assays using physiological cell systems), as well as in mechanisms of action studies, in vitro proof-of-concept and any type of analyses concerning imagine-based phenotypic measurements. By identification of some ADMET features at the stage of primary or secondary screening, it may make the drug discovery process more efficient in terms of time and resources.
The device can test new compounds with therapeutic potential in various areas, like neuroinflammatory and fibrotic diseases, addressing distinct limitations of existing therapies. It allows us to perform a wide variety of assays, which includes:
Functional live assays